Who are NRP104's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Propadrine, Didrex, Tenuate, Aramine, Vialin, lorcaserin + phentermine-HCl.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nrp104.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

NRP104 — Competitive Intelligence Brief

NRP104 (NRP104) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sympathomimetic amine; ADHD stimulant. Area: Neurology / Psychiatry.

phase 3 Sympathomimetic amine; ADHD stimulant Dopamine transporter (DAT); Norepinephrine transporter (NET) Neurology / Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

NRP104 (NRP104) — New River Pharmaceuticals. NRP104 is a prodrug that delivers d-amphetamine to the central nervous system for the treatment of attention-deficit/hyperactivity disorder (ADHD).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
NRP104 TARGET	NRP104	New River Pharmaceuticals	phase 3	Sympathomimetic amine; ADHD stimulant	Dopamine transporter (DAT); Norepinephrine transporter (NET)
Propadrine	PHENYLPROPANOLAMINE	Alpharma Us Pharms	marketed	Indirectly Acting Sympathomimetic Amines	Sodium-dependent noradrenaline transporter	2000-01-01
Didrex	BENZPHETAMINE	Pfizer	marketed	Sympathomimetic Amine Anorectic	Alpha-1A adrenergic receptor	1960-01-01
Tenuate	DIETHYLPROPION	ANI Pharmaceuticals	marketed	Sympathomimetic Amine Anorectic	Sodium-dependent dopamine transporter	1959-01-01
Aramine	METARAMINOL		marketed	Indirectly Acting Sympathomimetic Amines	Macrophage migration inhibitory factor	1954-01-01
Vialin	MEPHENTERMINE	Baxter	marketed	Indirectly Acting Sympathomimetic Amines	Alpha-1A adrenergic receptor	1951-01-01
lorcaserin + phentermine-HCl	lorcaserin + phentermine-HCl	Eisai Inc.	marketed	Combination weight-loss agent (5-HT2C agonist + sympathomimetic amine)	5-HT2C receptor (lorcaserin); norepinephrine release (phentermine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sympathomimetic amine; ADHD stimulant class)

New River Pharmaceuticals · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NRP104 — Competitive Intelligence Brief. https://druglandscape.com/ci/nrp104. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab